Selva Therapeutics, Inc.
Selva Therapeutics is a privately held biotechnology company dedicated to developing therapeutics for infectious diseases. Their lead compound, SLV213, is a broad-spectrum antiviral drug candidate with activity against SARS-CoV-2, Ebola, Nipah, and other viruses. The company focuses on rapid development of treatments for COVID-19 and other life-threatening infectious diseases, aiming to bring valuable therapies to the market.
Industries
biotechnology
health-care
pharmaceutical
Nr. of Employees
small (1-50)
Products
SLV213
An investigational orally bioavailable small-molecule inhibitor of host cysteine proteases (cathepsin L) developed to block viral spike activation and viral entry; advanced through preclinical studies and a completed Phase 1 clinical trial and positioned for Phase 2 outpatient studies.
SLV213
An investigational orally bioavailable small-molecule inhibitor of host cysteine proteases (cathepsin L) developed to block viral spike activation and viral entry; advanced through preclinical studies and a completed Phase 1 clinical trial and positioned for Phase 2 outpatient studies.
Expertise Areas
- Host-targeted antiviral development
- Small-molecule drug discovery
- Preclinical infectious disease models (including nonhuman primates)
- Clinical trial design and execution (Phase 1 and Phase 2 readiness)
Key Technologies
- Small-molecule cysteine protease inhibitors
- Host-directed antiviral mechanisms (cathepsin L inhibition)
- Cell-based viral infectivity assays
- Nonhuman primate infection models